0001567619-21-006025.txt : 20210310
0001567619-21-006025.hdr.sgml : 20210310
20210310173144
ACCESSION NUMBER: 0001567619-21-006025
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210308
FILED AS OF DATE: 20210310
DATE AS OF CHANGE: 20210310
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Campbell James H
CENTRAL INDEX KEY: 0001757390
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-10670
FILM NUMBER: 21730987
MAIL ADDRESS:
STREET 1: 10910 DOMAIN DRIVE, SUITE 300
CITY: AUSTIN
STATE: TX
ZIP: 78758
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HANGER, INC.
CENTRAL INDEX KEY: 0000722723
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093]
IRS NUMBER: 840904275
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10910 DOMAIN DRIVE
STREET 2: SUITE 300
CITY: AUSTIN
STATE: TX
ZIP: 78758
BUSINESS PHONE: 512-777-3800
MAIL ADDRESS:
STREET 1: 10910 DOMAIN DRIVE
STREET 2: SUITE 300
CITY: AUSTIN
STATE: TX
ZIP: 78758
FORMER COMPANY:
FORMER CONFORMED NAME: HANGER ORTHOPEDIC GROUP INC
DATE OF NAME CHANGE: 19920703
FORMER COMPANY:
FORMER CONFORMED NAME: SEQUEL CORP
DATE OF NAME CHANGE: 19890814
FORMER COMPANY:
FORMER CONFORMED NAME: CELLTECH COMMUNICATIONS INC
DATE OF NAME CHANGE: 19860304
4
1
doc1.xml
FORM 4
X0306
4
2021-03-08
0
0000722723
HANGER, INC.
HNGR
0001757390
Campbell James H
10910 DOMAIN DRIVE, SUITE 300
AUSTIN
TX
78758
0
1
0
0
SVP, Chief Clinical Officer
Common Stock
2021-03-08
4
A
0
4650
0
A
45926
D
Common Stock
2021-03-08
4
F
0
1425
23.99
D
44501
D
Stock Options (right to buy)
12.77
2027-05-19
Common Stock
27328
27328
D
Represents a grant of time-based restricted stock under the Company's 2019 Omnibus Incentive Plan ("Plan"), which vests to the extent of 25% annually beginning on the first anniversary date of the grant and cumulatively vests to the extent of 25% each year thereafter. The restricted stock being reported does not include the contingent right of the reporting person to receive up to 4,650 additional performance shares under the Plan based on the achievement of certain performance targets for the fiscal year 2021.
Reflects payment of tax liability by withholding shares of stock incident to vesting of restricted stock previously issued.
Consists of (i) unvested restricted shares totaling 4,650 shares of stock from an initial grant of 4,650 shares of restricted stock that begins to vest on March 8, 2022; (ii) unvested restricted shares totaling 3,873 shares of stock from an initial grant of 3,873 shares of restricted stock that begins to vest on March 9, 2021; (iii) unvested restricted shares totaling 4,556 shares of stock from an initial grant of 4,556 shares of restricted stock that begins to vest on March 9, 2021; (iv) unvested restricted shares and fully vested shares totaling 3,647 shares of stock from an initial grant of 4,405 shares of restricted stock made on March 8, 2019; [continued in next footnote]
(v) unvested restricted shares and fully vested shares totaling 4,322 shares of stock from an initial grant of 5,220 shares of restricted stock made on March 8, 2019; (vi) unvested restricted shares and fully vested shares totaling 5,691 shares of stock from an initial grant of 6,710 shares of restricted stock made on March 9, 2018; (vii) unvested restricted shares and fully vested shares totaling 3,623 shares of stock from an initial grant of 7,029 shares of restricted stock made on March 8, 2017; (viii) fully vested shares totaling 1,058 shares of stock from an initial grant of 3,000 shares of restricted stock made on October 11, 2016; and (ix) unvested restricted shares and fully vested shares totaling 2,025 shares of stock from an initial grant of 6,008 shares of restricted stock made on April 29, 2016.
Except as otherwise noted, all remaining unvested restricted shares will continue to vest at a rate of 25% per year of the original grant amount on the anniversary date of the grant.
Stock options were granted under the Company's Special Equity Plan and vest 1/3 on each of May 19, 2018, 2019 and 2020.
/s/ Jessica Lochmann Allen, Attorney-in-Fact for James H. Campbell
2021-03-10